Efmarodocokin Alfa Uses, Dosage, Side Effects and more
Efmarodocokin Alfa is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
| Attribute | Details |
|---|---|
| Trade Name | Efmarodocokin Alfa |
| Generic | Efmarodocokin alfa |
| Efmarodocokin alfa Other Names | Efmarodocokin alfa, IL 22-FC, IL-22Fc |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
How Efmarodocokin Alfa works
Efmarodocokin Alfa is a human IL-22Fc IgG4 fusion protein that activates the IL-22 pathway being investigated for inflammatory diseases. Studies show activation of STAT3 in primary human hepatocytes and human colon cell lines.
